PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.
The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.
Minoxidil's effectiveness varies due to differences in sulfotransferase enzyme levels in the scalp, affecting people with conditions like ASD, liver disease, and androgenic alopecia. Treatments like topical tretinoin, microneedling, and using minoxidil sulfate instead of regular minoxidil can improve results for those with low enzyme levels.
Potential treatments for hair loss, specifically the combination of liquid minoxidil and pyrilutamide, with some suggesting that adding finasteride may be beneficial.
Treatments for hair loss, including the effectiveness and safety of Pyrilutamide compared to RU58841; experiences using both medications with varying results; and recommendations to try Pyrilutamide instead of RU58841.
Melatonin is being considered as a potential treatment for androgenic alopecia, with some users discussing its effects and combining it with other treatments like minoxidil and finasteride. Concerns about melatonin's impact on hormones and side effects from other treatments like ketoconazole were also discussed.
The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.
The conversation is about hair loss treatments, with users recommending finasteride and minoxidil as effective solutions. Some users report side effects, but overall, the consensus is to use these treatments rather than waiting for a cure.
A user is asking about the effectiveness and dosage of RU58841 for hair loss, comparing it to Minoxidil and discussing its long-term use alongside Finasteride. They plan to use RU58841 and Finasteride for several years before potentially switching to GT20029.
The conversation discusses using RU58841, a research chemical, for hair loss treatment. The user plans to use it due to side effects from finasteride and minoxidil, despite skepticism about its effectiveness and lack of FDA approval.
A medical student experienced hair loss slowing with Finasteride but developed severe, treatment-resistant insomnia. They tried various medications with little effect, suspecting Post-Finasteride Syndrome, and others suggested the insomnia might be linked to Finasteride's impact on neurosteroids.
Nutrafol is criticized for misleading advertising, as it doesn't effectively regrow hair. Effective treatments mentioned include minoxidil and finasteride.
A new topical finasteride has been approved in France, providing an alternative to oral finasteride with potentially fewer side effects. Users discuss the pros and cons of topical versus oral treatments, with some opting to create their own solutions to save money.
Rosemary Oil may inhibit the activity of 5α-Reductase, potentially promoting hair growth. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.
The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.
A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.
Research and science related to a minor improvement in hair growth caused by the use of verteporfin, as well as potential treatments such as Minoxidil, Finasteride, and RU58841.
The conversation discusses using higher doses of minoxidil and finasteride, considering dutasteride, and exploring other treatments like RU58841 for hair preservation. The user reports no side effects after six months and is interested in advanced treatment combinations.
The post discusses the side effects of various drugs causing excess hair growth, questioning why only minoxidil is used in the hair loss industry. The conversation includes users sharing their experiences and concerns about potential side effects of these drugs, with some preferring baldness over potential health risks.
The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.
The conversation is about treating hair loss without finasteride or dutasteride due to sensitivity causing gynecomastia. The user plans to use pyrilutamide, RU58841, and oral Minoxidil instead.
The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.
Hair loss treatments, specifically the use of finasteride, microneedling and potentially oral minoxidil. People discussed their experiences with finasteride, its effects on sexual behaviors, as well as potential solutions such as tadalafil or using other growth factor signal peptides for hope in curing male pattern baldness.
Caffeine may interfere with oral minoxidil because caffeine increases blood pressure while minoxidil lowers it. Users discuss potential interactions and effects on hair loss treatment.
The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.
Using a combination of low-dose oral and topical finasteride, along with minoxidil, may effectively manage hair loss by targeting both systemic and local DHT. Users report positive experiences with this regimen, noting good tolerability and no worsening of hair condition.
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.
Be skeptical of claims about new baldness cures; current treatments like finasteride, dutasteride, and minoxidil remain the best options. New products like Breezula and PP405 lack compelling evidence and may not be available soon.